PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge. The goal of the Children's Oncology Group (COG) AALL01P2 study was to develop a safe and active chemotherapy reinduction platform, which could be used to evaluate novel agents in future trials. PATIENTS AND METHODS: One hundred twenty-four patients with ALL and first marrow relapse received three, 35-day blocks of reinduction chemotherapy: 69 with early relapse (ER; < 36 months from initial diagnosis) and 55 with late relapse (LR). Minimal residual disease (MRD) was measured by flow cytometry after each treatment block. RESULTS: Second complete remission (CR2) rates at the end of block 1 in 117 assessable patients were 68% +/- 6% for ER (n = 63) and 96% +/- 3% for LR (n = 54; P < .0001). Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2. Among patients in CR2, MRD greater than 0.01% was detected at the end of block 1 in 75% +/- 7% of ER (n = 36) versus 51% +/- 8% of LR (n = 43; P = .0375) and 12-month event-free survival was 80% +/- 7% versus 58% +/- 7% in MRD-negative versus positive patients (P < .0005). Blocks 2 and 3 of therapy resulted in reduction of MRD burden in 40 of 56 patients who were MRD positive after block 1. Toxicity was acceptable during all three blocks with five deaths (4%) from infections. CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL. Alternative strategies are needed for T-ALL. Serial MRD measurements were feasible and prognostic of outcome.
RCT Entities:
PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge. The goal of the Children's Oncology Group (COG) AALL01P2 study was to develop a safe and active chemotherapy reinduction platform, which could be used to evaluate novel agents in future trials. PATIENTS AND METHODS: One hundred twenty-four patients with ALL and first marrow relapse received three, 35-day blocks of reinduction chemotherapy: 69 with early relapse (ER; < 36 months from initial diagnosis) and 55 with late relapse (LR). Minimal residual disease (MRD) was measured by flow cytometry after each treatment block. RESULTS: Second complete remission (CR2) rates at the end of block 1 in 117 assessable patients were 68% +/- 6% for ER (n = 63) and 96% +/- 3% for LR (n = 54; P < .0001). Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2. Among patients in CR2, MRD greater than 0.01% was detected at the end of block 1 in 75% +/- 7% of ER (n = 36) versus 51% +/- 8% of LR (n = 43; P = .0375) and 12-month event-free survival was 80% +/- 7% versus 58% +/- 7% in MRD-negative versus positive patients (P < .0005). Blocks 2 and 3 of therapy resulted in reduction of MRD burden in 40 of 56 patients who were MRD positive after block 1. Toxicity was acceptable during all three blocks with five deaths (4%) from infections. CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL. Alternative strategies are needed for T-ALL. Serial MRD measurements were feasible and prognostic of outcome.
Authors: C Eckert; A Biondi; K Seeger; G Cazzaniga; R Hartmann; B Beyermann; M Pogodda; J Proba; G Henze Journal: Lancet Date: 2001-10-13 Impact factor: 79.321
Authors: P Bader; J Hancock; H Kreyenberg; N J Goulden; D Niethammer; A Oakhill; C G Steward; R Handgretinger; J F Beck; T Klingebiel Journal: Leukemia Date: 2002-09 Impact factor: 11.528
Authors: M J Borowitz; D J Pullen; J J Shuster; D Viswanatha; K Montgomery; C L Willman; B Camitta Journal: Leukemia Date: 2003-08 Impact factor: 11.528
Authors: Anna Maria Testi; Ilaria Del Giudice; William Arcese; Maria Luisa Moleti; Fiorina Giona; Giuseppe Basso; Andrea Biondi; Valentino Conter; Chiara Messina; Roberto Rondelli; Alessandra Micozzi; Concetta Micalizzi; Elena Barisone; Franco Locatelli; Giorgio Dini; Maurizio Aricò; Fiorina Casale; Margherita Comis; Saverio Ladogana; Alma Lippi; Rossella Mura; Marie France Pinta; Nicola Santoro; Maria Grazia Valsecchi; Giuseppe Masera; Franco Mandelli Journal: Br J Haematol Date: 2002-09 Impact factor: 6.998
Authors: Judith M Chessells; Paul Veys; Helena Kempski; Patricia Henley; Ali Leiper; David Webb; Ian M Hann Journal: Br J Haematol Date: 2003-11 Impact factor: 6.998
Authors: E Coustan-Smith; A Gajjar; N Hijiya; B I Razzouk; R C Ribeiro; G K Rivera; J E Rubnitz; J T Sandlund; M Andreansky; M L Hancock; C-H Pui; D Campana Journal: Leukemia Date: 2004-03 Impact factor: 11.528
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Weili Sun; Etan Orgel; Jemily Malvar; Richard Sposto; Jennifer J Wilkes; Rebecca Gardner; Vanessa P Tolbert; Alison Smith; Minjun Hur; Jill Hoffman; Susan R Rheingold; Michael J Burke; Alan S Wayne Journal: Pediatr Blood Cancer Date: 2016-07-20 Impact factor: 3.167
Authors: Stuart S Winter; Jerec Ricci; Li Luo; Debbie M Lovato; Hadya M Khawaja; Tasha Serna-Gallegos; Natalie Debassige; Richard S Larson Journal: Health (Irvine Calif) Date: 2013-05
Authors: Karen L Bride; Tiffaney L Vincent; Soo-Yeon Im; Richard Aplenc; David M Barrett; William L Carroll; Robin Carson; Yunfeng Dai; Meenakshi Devidas; Kimberly P Dunsmore; Tori Fuller; Tina Glisovic-Aplenc; Terzah M Horton; Stephen P Hunger; Mignon L Loh; Shannon L Maude; Elizabeth A Raetz; Stuart S Winter; Stephan A Grupp; Michelle L Hermiston; Brent L Wood; David T Teachey Journal: Blood Date: 2018-01-05 Impact factor: 22.113
Authors: Leonid Karawajew; Michael Dworzak; Richard Ratei; Peter Rhein; Giuseppe Gaipa; Barbara Buldini; Giuseppe Basso; Ondrej Hrusak; Wolf-Dieter Ludwig; Günter Henze; Karl Seeger; Arend von Stackelberg; Ester Mejstrikova; Cornelia Eckert Journal: Haematologica Date: 2015-05-22 Impact factor: 9.941
Authors: Sunil S Raikar; Lauren C Fleischer; Robert Moot; Andrew Fedanov; Na Yoon Paik; Kristopher A Knight; Christopher B Doering; H Trent Spencer Journal: Oncoimmunology Date: 2017-12-26 Impact factor: 8.110
Authors: Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544